Oncoinvent ASA (0RU5) Share Price & Analysis

1 Followers

0RU5 Stock Chart & Stats

kr 66.40kr 0.00(0.00%)

At close: Nov 11 4:30 PM GMT

Day’s Range: NOK 66.40 - NOK 66.40
52-Week Range: NOK 40.20 - NOK 141.50
Previous Close: NOK 66.40
Volume: N/A
Average Volume (3M): 529
Market Cap: NOK 404.48M
Enterprise Value: NOK 120.97M
Total Cash (Recent Filing): NOK 140.16M
Total Debt (Recent Filing): NOK 818.00K
Price to Earnings (P/E): ―
Beta: -0.14
Next Earnings: Nov 17, 2026 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Mar 15, 2022
Dividend Yield: N/A

Oncoinvent ASA News

Oncoinvent bolsters Radspherin programme with Phase 2 progress and NOK 148.5m raise

Oncoinvent ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA reported continued clinical and operational progress, highlighting recruitment of 16 additional patients to its Phase 2 ovarian cancer trial,

2w agoBRRGF 7BG

Oncoinvent sets investor webcast as it advances radiopharmaceutical cancer therapy

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA will host a live webcast for investors, analysts, and other stakeholders on 28 October 2026 at 10:00

3w agoBRRGF 7BG

Oncoinvent Cancels Planned Subsequent Share Offering After Price Slump

Oncoinvent ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA has decided to cancel its planned subsequent repair offering of up to 200,000 new shares, which was intended to

1M agoBRRGF 7BG

Oncoinvent Completes Private Placement as Linc AB Stake Rises to 12.21%

The latest announcement is out from Oncoinvent ASA ( ($BRRGF) ). Oncoinvent ASA has completed the share capital increase tied to its recent private placement and retail offering of 1,650,000

1M agoBRRGF 7BG

Hadean Ventures Funds Lift Oncoinvent Stake to Over 12% After Private Placement

Oncoinvent ASA ( ($BRRGF) ) has shared an announcement. Oncoinvent ASA has completed a NOK 90-per-share private placement and related share lending arrangements, leading to the re-delivery of 554,327 temporarily

1M agoBRRGF 7BG

Oncoinvent Registers Share Capital Increase After Private Placement

Oncoinvent ASA ( ($BRRGF) ) has provided an announcement. Oncoinvent ASA has completed the registration of a share capital increase following a previously announced private placement and a retail offering,

1M agoBRRGF 7BG

Oncoinvent’s Radspherin Program Gains Spotlight at EANM and ESMO 2026

Oncoinvent ASA ( ($BRRGF) ) has shared an update. Oncoinvent ASA, a clinical-stage radiopharmaceutical developer, is advancing Radspherin[®], an alpha-emitting intraperitoneal therapy aimed at eradicating residual micrometastatic cancer cells following

1M agoBRRGF 7BG

Oncoinvent Details Insider Allocation in Retail Share Offering

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA has announced details related to its previously communicated retail share offering, specifically highlighting the allocation of shares

1M agoBRRGF 7BG

Oncoinvent Shares Begin Trading Ex-Rights Ahead of Planned Offering

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA announced that, as of 23 September 2026, its shares are trading ex-rights, meaning existing and new shareholders

1M agoBRRGF 7BG

Hadean Ventures Funds Adjust Oncoinvent Stake Amid Private Placement Settlement

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA has completed a private placement of 1,650,000 new shares at NOK 90 per share, triggering a series

1M agoBRRGF 7BG

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on BerGenBio to NOK 38 from NOK 70 and keeps a Buy rating on the shares post the Q2 report.

2y agoBRRGF 7BG0

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK 1, down from NOK 9. The analyst sees the terms of the

3y agoBRRGF 7BG

BerGenBio downgraded to Sell from Hold at DNB Markets

DNB Markets downgraded BerGenBio to Sell from Hold with a NOK 1 price target. Published first on TheFly See today’s best-performing stocks on TipRanks >>

3y agoBRRGF 7BG

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now is an opportune time to step off the sidelines with BerGenBio, with

3y agoBRRGF

0RU5 FAQ

What was Oncoinvent ASA’s price range in the past 12 months?

Oncoinvent ASA lowest share price was kr 40.20 and its highest was kr 141.50 in the past 12 months.

What is Oncoinvent ASA’s market cap?

Oncoinvent ASA’s market cap is kr 404.48M.

When is Oncoinvent ASA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Oncoinvent ASA’s earnings last quarter?

Oncoinvent ASA released its earnings results on Aug 27, 2026. The company reported -kr 15.2 earnings per share for the quarter.

Is Oncoinvent ASA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Oncoinvent ASA pay dividends?

Oncoinvent ASA pays a dividend of kr 0.285 which represents an annual dividend yield of ―. See more information on Oncoinvent ASA dividends here

What is Oncoinvent ASA’s EPS estimate?

Oncoinvent ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oncoinvent ASA have?

Oncoinvent ASA has 6,128,412 shares outstanding.

What happened to Oncoinvent ASA’s price movement after its last earnings report?

Oncoinvent ASA reported an EPS of -kr 15.2 in its last earnings report. Following the earnings report the stock price went up 8.899%.

Which hedge fund is a major shareholder of Oncoinvent ASA?

Currently, no hedge funds are holding shares in GB:0RU5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oncoinvent ASA

Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.

Oncoinvent ASA (0RU5) Earnings & Revenues

Historic Earnings Reports

0RU5 Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was predominantly positive, with strong Phase II recruitment, expanding clinical infrastructure, stable cash burn, a NOK 148.5 million financing, runway into the second half of 2027 and active preparation for Phase III. The principal challenges were the April delay for a more mature efficacy readout, the still-unknown efficacy results, unresolved elements of the Phase III design and the need for additional funding or partners to finance a full Phase III study.

View all GB:0RU5 earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	8	1	12
Technical Analysis	4	1	4
Moving Averages	4	0	8

Technical Analysis >

Similar Stocks

Stocks similar to GB:0RU5
Company	Price & Change	Follow
BRRGFOncoinvent ASA
CLRBCellectar Biosciences
FENCFennec Pharmaceuticals
GERNGeron
KZIAKazia Therapeutics
SRNESorrento Therapeutics

Compare GB:0RU5 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

0RU5 Stock Chart & Stats

Oncoinvent ASA News

Oncoinvent bolsters Radspherin programme with Phase 2 progress and NOK 148.5m raise

Oncoinvent sets investor webcast as it advances radiopharmaceutical cancer therapy

Oncoinvent Cancels Planned Subsequent Share Offering After Price Slump

Oncoinvent Completes Private Placement as Linc AB Stake Rises to 12.21%

Hadean Ventures Funds Lift Oncoinvent Stake to Over 12% After Private Placement

Oncoinvent Registers Share Capital Increase After Private Placement

Oncoinvent’s Radspherin Program Gains Spotlight at EANM and ESMO 2026

Oncoinvent Details Insider Allocation in Retail Share Offering

Oncoinvent Shares Begin Trading Ex-Rights Ahead of Planned Offering

Hadean Ventures Funds Adjust Oncoinvent Stake Amid Private Placement Settlement

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

BerGenBio downgraded to Sell from Hold at DNB Markets

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

0RU5 FAQ

Company Description

Oncoinvent ASA

Oncoinvent ASA (0RU5) Earnings & Revenues

0RU5 Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive